Sinopharm Group Files Director List with HKEX

Sinopharm Group Co. Ltd. has filed an updated list of directors and their roles with the Hong Kong Stock Exchange. The board consists of Non-Executive Directors Jin Bin (Chairman), Chen Qiyu, Zu Jing, Xing Yonggang, Ma Yue, Chen Yuqing, Wen Deyong, and Li Ying; Executive Directors Lian Wanyong (President) and Yang Binghua; and Independent Non-Executive Directors Li Peiyu, Wu Tak Lung, Yu Weifeng, Shi Shenghao, and Chen Weiru. Jin Bin serves as Chairman of both the Nomination and Strategy and Investment Committees and is a member of the Legal and Compliance and ESG Committee. Chen Qiyu is a member of the Strategy and Investment Committee. Lian Wanyong is a member of both the Strategy and Investment Committee and the Legal and Compliance and ESG Committee. Li Peiyu is Chairman of the Remuneration Committee and a member of the Audit, Strategy and Investment, and Legal and Compliance and ESG Committees. Wu Tak Lung chairs the Audit Committee and is a member of the Remuneration Committee and Nomination Committee. Yu Weifeng leads the Legal and Compliance and ESG Committee and is a member of the Remuneration and Nomination Committees. Shi Shenghao is a member of the Audit, Nomination, and Strategy and Investment Committees. Chen Weiru is a member of the Nomination and Strategy and Investment Committees. Other directors also hold various committee roles, reflecting a broad distribution of responsibilities across governance, strategy, compliance, remuneration, and nomination functions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251219-11961543), on December 19, 2025, and is solely responsible for the information contained therein.